Nature Search

P-glycoprotein: from genomics to mechanism

Suresh V Ambudkar
Chava Kimchi-Sarfaty
Michael M Gottesman
Reviews23 Oct 2003
Oncogene

Volume: 22, P: 7468-7485
Engineering and evaluation of FXa bypassing agents that restore hemostasis following Apixaban associated bleeding

Direct oral anticoagulants (DOACs) targeting factor Xa that are used to prevent or treat thromboembolic disorders carry the risk of uncontrolled bleeding. Here, the authors present the computational design and evaluation of factor Xa-variants which can be used to reduce DOAC-associated bleeding.

Wojciech Jankowski
Stepan S. Surov
Zuben E. Sauna
ResearchOpen Access09 May 2024
Nature Communications

Volume: 15, P: 1-9
Understanding the contribution of synonymous mutations to human disease

This Review presents the growing evidence that mutations that do not cause a change in amino acid sequence — synonymous mutations — contribute to human disease. Such mutations may act at different stages of gene expression, including mRNA processing, translation initiation and elongation or protein folding.

Zuben E. Sauna
Chava Kimchi-Sarfaty
Reviews31 Aug 2011
Nature Reviews Genetics

Volume: 12, P: 683-691
Cas9-derived peptides presented by MHC Class II that elicit proliferation of CD4⁺ T-cells

There have been reports of immune responses against Cas9 which may impair clinical use. Here the authors scan a cohort comparable to the North American population vis-à-vis distribution of MHC-II variants to identify Cas9 peptides presented by MHC-II proteins and can stimulate CD4 + T-cells.

Vijaya L. Simhadri
Louis Hopkins
Zuben E. Sauna
ResearchOpen Access24 Aug 2021
Nature Communications

Volume: 12, P: 1-7
Endogenous factor VIII synthesis from the intron 22–inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A

Patients with hemophilia lacking functional coagulation factor VIII (FVIII) are treated with replacement FVIII proteins. The development of neutralizing antibodies to the replacement FVIII, a major clinical problem, depends on the nature of the mutation in the gene encoding FVIII. The authors find that a prevalent inversion allele can unexpectedly produce FVIII protein, explaining why individuals with this allele do not frequently develop neutralizing antibodies.

Gouri Shankar Pandey
Chen Yanover
Elaine Reed
Research15 Sept 2013
Nature Medicine

Volume: 19, P: 1318-1324
Investigation of thrombin concentration at the time of clot formation in simultaneous thrombin and fibrin generation assays

Ivan D. Tarandovskiy
Stepan S. Surov
Mikhail V. Ovanesov
ResearchOpen Access22 Apr 2024
Scientific Reports

Volume: 14, P: 1-10
Pharmacogenetics and the immunogenicity of protein therapeutics

Chen Yanover
Nisha Jain
Zuben E Sauna
Correspondence13 Oct 2011
Nature Biotechnology

Volume: 29, P: 870-873
Modified aptamers as reagents to characterize recombinant human erythropoietin products

Wojciech Jankowski
H. A. Daniel Lagassé
Zuben E. Sauna
ResearchOpen Access29 Oct 2020
Scientific Reports

Volume: 10, P: 1-11
A structural homology approach to identify potential cross-reactive antibody responses following SARS-CoV-2 infection

Joseph R. McGill
H. A. Daniel Lagassé
Zuben E. Sauna
ResearchOpen Access06 Jul 2022
Scientific Reports

Volume: 12, P: 1-31
Endotoxin contamination in commercially available Cas9 proteins potentially induces T-cell mediated responses

Vijaya L. Simhadri
Joseph R. McGill
Zuben E. Sauna
Research08 Nov 2021
Gene Therapy

Volume: 30, P: 575-580
Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies

Aikaterini Alexaki
Gaya K. Hettiarachchi
Chava Kimchi-Sarfaty
ResearchOpen Access29 Oct 2019
Scientific Reports

Volume: 9, P: 1-15

Search

Filter By:

Search

Quick links